Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+and HER2-low breast cancer models

被引：2
|
作者：
Proia, Theresa
Wallez, Yann
Bashi, Azadeh Cheraghchi
Wilson, Zena
Randle, Suzanne
Anderton, Mark
Carroll, Danielle
Rasheed, Zeshaan
Pease, J. Elizabeth
Leo, Elisabetta
Mettetal, Jerome
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-13-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-13-18
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2025, 21 (04) : 367 - 380
  • [42] Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
    Pourjamal, Negar
    Le Joncour, Vadim
    Vereb, Gyorgy
    Honkamaki, Cilla
    Isola, Jorma
    Leyton, Jeffrey, V
    Laakkonen, Pirjo
    Joensuu, Heikki
    Barok, Mark
    TRANSLATIONAL ONCOLOGY, 2025, 53
  • [43] Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
    Zhan, Mei
    Huang, Zijia
    Xu, Ting
    Xu, Xinyi
    Zheng, Hanrui
    Wu, Fengbo
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [44] Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer
    Dickerson, James
    Moen, Marcus
    Nielsen, Perry
    Tran, Edward
    Suen, Wesley
    Goldhaber-Fiebert, Jeremy D.
    Alarid-Escudero, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial
    Perez-Garcia, Jose Manuel
    Batista, Marta Vaz
    Cortez-Castedo, Patricia
    Borrego, Manuel Ruiz
    Cejalvo, Juan Miguel
    de la Haba-Rodriguez, Juan
    Garrigos, Laia
    Racca, Fabriccio
    Servitja, Sonia
    Blanch, Salvador
    Gion, Maria
    Nave, Monica
    Fernandez, Adela
    Martinez-Bueno, Alejandro
    Llombart-Cussac, Antonio
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cortes, Javier
    Braga, Sofia
    CANCER RESEARCH, 2023, 83 (05)
  • [47] HER2-Low Breast Cancer Can Be Visualized by HER2 PET
    Altena, Renske
    af Buren, Siri
    Tran, Thuy
    Axelsson, Rimma
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1842 - 1842
  • [48] Improving HER2 testing reproducibility in HER2-low breast cancer
    Sajjadi, Elham
    Venetis, Konstantinos
    Ivanova, Mariia
    Fusco, Nicola
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 882 - 888
  • [49] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [50] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
12345